Although GLP-1s are showing knock-on benefits for a variety of symptoms and conditions, theres reason for caution
In practical terms, we must generate MS/MS fragmentation that covers the entire 31-amino-acid sequence and decisively identifies the modified residues
Understanding variants in GLP1R, GIPR, FTO, and MC4R can support a more informed conversation with your provider about whether a lower-cost microdose protocol or a higher-potency compound better aligns with your predicted metabolic response
For NSAIDs, use the lowest effective dose for the shortest duration to minimize risks, and avoid them if there is a history of ulcers, kidney disease, or significant cardiovascular issues
The numbers depend on the dose and the population